玻璃体腔注射阿瓦斯汀、雷珠单克隆抗体后糖尿病视网膜患者血清中VEGF含量的变化研究  

Serum vascular endothelial growth factor after intravitreal injection of bevacizumab and ranibizumab in patients with diabetic retinopathy

作　　者：单俊杰[1] 袁志兰[2] 曹国平[1] 

机构地区：[1]江苏省泰州市人民医院眼科,225300 [2]江苏省人民医院眼科,210029

出　　处：《临床眼科杂志》2015年第4期330-332,共3页Journal of Clinical Ophthalmology

摘　　要：目的研究玻璃体腔注射阿瓦斯汀、雷珠单克隆抗体后增生性糖尿病视网膜病变(PDR)患者血清中VEGF的变化。方法收集玻璃体腔注射阿瓦斯汀、雷珠单抗后PDR患者血清样本(注射当天,注射后7 d,注射后28 d),并以注射当天的血清样本为基准值作为对照,用ELISA方法测定血清中VEGF的含量。结果玻璃体腔注射阿瓦斯汀术后,所有样本血清中VEGF含量都降低,降低幅度在术后7 d达到最大峰值,术后28 d VEGF有所上升,但仍未达到术前水平。玻璃体腔注射雷珠单抗术后,所有样本中VEGF含量无显著下降。结论一次玻璃体腔注射阿瓦斯汀术后,血清中VEGF含量降低并且维持相当时间,说明阿瓦斯汀进入到血液循环中,因此有必要密切关注阿瓦斯汀玻璃体腔注射后的系统性影响和对未注射眼的影响,而雷珠单抗对全身血液系统中VEGF含量无明显影响,从对全身影响安全性角度来看,雷珠单抗优于阿瓦斯汀。Objective Avastin （ bevacizumab） and Lucentis （ ranibizumab） intravitreal injections are widely used for treatment of diabetic retinopathy.This study is to determine the serum concentrations of vascular endothelial growth fac-tor （ VEGF） in patients with diabetic retinopathy after intravitreal injection of bevacizumab and ranibizumab.Methods Twenty-six patients （26 eyes） with active proliferative diabetic retinopathy were investigated.Thirteen patients received 1.25 mg bevacizumab and the rest received 0.5 mg ranibizumab.VEGF concentration was measured by ELISA technique on the day of administration and on 7th and 28th days after injection.Results In all participants treated with bevacizumab, maximal reduction of serum VEGF was noted on the 7th day.At 28th day, serum VEGF increased but did not reach base-line level in most of patients.No signi cant reduction of VEGF level was observed in patients receiving ranibizumab.Con-clusion Bevacizumab signi cantly reduces the serum VEGF level for up to one month in patients with proliferative diabetic retinopathy.No signi cant systemic side effects of intravitreal ranibizumab were observed.

关 键 词：增生性糖尿病视网膜病变 血管内皮细胞生长因子 贝伐单抗 雷珠单抗 

分 类 号：R587.2[医药卫生—内分泌]